Sort
1,049,261 grants matching “t cell”
Center for Pre-Clinical Cancer Research
$2,118,025Joseph Francis · Louisiana State Univ A&M Col Baton Rouge · P20 · FY2024 · GM
Arabidopsis 2010: Analysis of Two-Component Signaling Elements from Arabidopsis
$2,118,000Joseph J Kieber · University Of North Carolina At Chapel Hill · · FY2001 · BIO
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
$2,117,925Robert C Bast · University Of Tx Md Anderson Can Ctr · P50 · FY2011 · CA
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma
$2,117,897Lisa Rimsza · Mayo Clinic Arizona · P01 · FY2021 · CA
Clinical and Molecular Studies of Malformations
$2,117,786Leslie Biesecker · National Human Genome Research Institute · ZIA · FY2010 · HG
PHYSIOLOGICAL CONSEQUENCES OF PULMONARY DISEASE
$2,117,731University Of California San Diego · P01 · FY2002 · HL
Identification of human genes of iron homeostasis
$2,117,630Caroline Philpott · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Specialized Program Of Research Excellence (SPORE) in Leukemia.
$2,117,606Daniel C Link · Washington University · P50 · FY2019 · CA
Blood Pressure-Determinants & Controllers
$2,117,519Allen W Cowley · Medical College Of Wisconsin · P01 · FY2007 · HL
Cleveland Alzheimer's Disease Research Center
$2,117,487James Bruce Leverenz · Cleveland Clinic Lerner Com-Cwru · P30 · FY2019 · AG
Mechanisms and Markers of Prostate Cancer Metastases
$2,117,386University Of Washington · P01 · FY2005 · CA
Molecular Regulation of Stem Cell Aging
$2,117,285Thomas A Rando · Stanford University · P01 · FY2019 · AG
RNAi and Epigenetic Control of Higher-Order Chromatin Assembly
$2,117,192Shivinder S Grewal · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Molecular Basis of Myelopoiesis
$2,117,040Bernard G Forget · Yale University · P01 · FY2007 · HL
Signaling of Endothelial Permeability and Lung Injury
$2,117,037Asrar B. Malik · University Of Illinois At Chicago · P01 · FY2007 · HL
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.
$2,117,028Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL
Intracellular pathogens and innate immunity
$2,116,986Daniel A Portnoy · University Of California Berkeley · P01 · FY2017 · AI
Cancer Center Support Grant
$2,116,924Robert S. Dipaola · Rbhs -Cancer Institute Of New Jersey · P30 · FY2013 · CA
Enhancement of Cancer Research at Clark Atlanta University
$2,116,902Shafiq A Khan · Clark Atlanta University · U54 · FY2020 · MD
Cell Autonomous and Non-Autonomous Mechanisms of Aging
$2,116,821Paul D. Robbins · Scripps Florida · P01 · FY2016 · AG
(A) PHOEBUS OPTOELECTRONICS' PRIMARY OBJECTIVE IS TO DEVELOP A HYPERSPECTRAL IMAGING TECHNOLOGY THE METAMATERIAL SPECTROMETER (MS) WHICH MINIMIZES THE TRADEOFFS BETWEEN PERFORMANCE AND THE SIZE WEIGHT AND POWER (SWAP). OUR MS TECHNOLOGY PROVIDES A COMPETITIVE ADVANTAGE OVER CONVENTIONAL OPTICAL SYSTEMS BY ENABLING THE SENSOR TO BE MORE NARROWLY TARGETED THE SPECTRAL BANDS OF INTEREST FOR MEASURING TRACE GASES AND AEROSOLS IN THE EARTH'S ATMOSPHERE. ADDITIONAL OBJECTIVES THAT WILL BE MET ARE: DEMONSTRATE A SWAP REDUCTION RELATIVE TO CURRENT HYPERSPECTRAL SYSTEMS. DEMONSTRATE IMPROVED SPECTROSCOPIC PERFORMANCE RELATIVE TO CURRENT SYSTEMS. PRODUCE SENSOR DATASETS TO QUANTIFY ATMOSPHERIC CONSTITUENTS OR SPECTRAL INDICES FOR LAND AND VEGETATION CHARACTERIZATION. PRODUCE SENSOR DATASETS OF GASES RELEVANT TO EARTH SCIENCE MEASUREMENTS OF THE ATMOSPHERE. MINIMIZE THE TOTAL COST OF THE HYPERSPECTRAL SENSING SYSTEM WHILE MAINTAINING STATE-OF-THE-ART PERFORMANCE. DEMONSTRATE REDUCTION IN DATA PROCESSING TIMES AS A RESULT OF SPECTRAL CHANNEL OPTIMIZATION AND BANDWIDTH PERFORMANCE OF THE METAMATERIAL. PROVIDE A FRAMEWORK AND TESTING PLATFORM TO TAILOR FUTURE ITERATIONS OF THE TECHNOLOGY TO SPECIFIC SENSING MISSIONS. DEVELOP THE FUNDAMENTAL CONCEPTS OF THE TECHNOLOGY TO EXPAND IT TO OTHER SPECTRAL BANDS FROM THE VISIBLE TO THE LWIR. THE ANTICIPATED BENEFITS OF THE PROPOSED TECHNOLOGY ARE: INCORPORATING MANY PIXEL-SCALE FILTERS ELIMINATES THE NEED FOR A DISPERSIVE ELEMENT WITHIN THE SYSTEM. SELECTABLE CHANNELS WITH VARYING PASSBANDS MEASURE ONLY DESIRED CHANNELS SHRINKING DETECTOR ELECTRONICS AND DATA RATE NEEDS. COMPATIBILITY WITH FAST OPTICAL SYSTEMS MAKES BEST USE OF AVAILABLE SIGNAL MINIMIZING APERTURE SIZE FOR A GIVEN MEASUREMENT PERFORMANCE. ENABLE HYPERSPECTRAL FILTERING TECHNOLOGY TO BE USED WITH MINIATURE SPACE PLATFORMS SUCH AS CUBESATS. PROVIDE A FLEXIBLE AND COST-MINDED HYPERSPECTRAL IMAGING PLATFORM FOR A VARIETY OF SPECTRAL BANDS. EXTEND THE MS TECHNOLOGY FOR USE IN SPACE-BASED APPLICATIONS SUCH AS LONG-RANGE LASER COMMUNICATION. (B) THE OUTLINE FOR THE PROPOSED WORK AND METHODOLOGY IS AS FOLLOWS: SIMULATE THE MS FILTER DESIGN FROM THE UNIT CELL TO THE FINITE SCALE STRUCTURES USING INDUSTRY STANDARD ELECTROMAGNETIC SIMULATION SOFTWARE TO OPTIMIZE IN-BAND TRANSMISSION AND OUT-OF-BAND REJECTION. FABRICATE OPTIMIZED DESIGNS USING STANDARD CMOS MICRO-FABRICATION TECHNOLOGIES. OPTICALLY CHARACTERIZE FABRICATED TEST STRUCTURES AND COMPARE PERFORMANCE TO SIMULATED PREDICTIONS. USE OPTICAL CHARACTERIZATION DATA TO REFINE SIMULATIONS OPTIMIZE DESIGNS FABRICATE IMPROVED TEST STRUCTURES AND REPEAT OPTICAL TESTS. ITERATE STEP 4 UNTIL TEST STRUCTURES DEMONSTRATE PERFORMANCE REQUIRED FOR A PROTOTYPE LEVEL DEVICE. FABRICATE AND OPTICALLY CHARACTERIZE THE FULL PROTOTYPE FILTER AS A STANDALONE DEVICE. INTEGRATE THE MS FILTER INTO A COMPLETE OPTICAL SYSTEM FOR MORE IN-DEPTH SYSTEM-LEVEL TESTING (TO BE PERFORMED BY OUR INDUSTRY PARTNER.) QUANTIFY RELEVANT PERFORMANCE DATA OF THE PROTOTYPE SYSTEM AND ESTIMATE THE IMPROVEMENT TO EARTH SCIENCE MEASUREMENTS. (C) PERIOD OF PERFORMANCE: 3 YEARS (D) ENTRY TRL 2 EXIT TRL 5
$2,116,714Phoebus Optoelectronics Llc · · FY2020 · National Aeronautics and Space Administration
Immunopathogenesis of Fungal Infections
$2,116,544Michail Lionakis · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Visual Sciences Center of Biomedical Research Excellence
$2,116,460Visvanathan Ramamurthy · West Virginia University · P20 · FY2022 · GM
Pathophysiology and Treatment of Fanconi's Anemia
$2,116,459Markus Grompe · Oregon Health & Science University · P01 · FY2010 · HL
Genomic Resource for the Yeast Saccharomyces
$2,116,404Joe Michael Cherry · Stanford University · U41 · FY2019 · HG